Published in J Acquir Immune Defic Syndr on January 01, 1992
Systemic effects of inflammation on health during chronic HIV infection. Immunity (2013) 2.34
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS (2008) 1.20
Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg (2007) 1.15
HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis (2011) 1.11
HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc (2013) 1.04
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS (2014) 0.96
Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. J Int AIDS Soc (2005) 0.93
Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS (2010) 0.87
Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. Curr HIV/AIDS Rep (2015) 0.78
Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr (2013) 0.76
Acquired protein S deficiency. J Acquir Immune Defic Syndr (1993) 0.75
Hematologic manifestations in a child with HIV; a Case Report. Iran J Ped Hematol Oncol (2012) 0.75
Late onset Warfarin induced skin necrosis in human immunodeficiency virus infected patient with pulmonary tuberculosis. Indian J Sex Transm Dis (2013) 0.75
Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. MedGenMed (2005) 0.75
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet (1981) 2.80
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature (1990) 2.61
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection. J Infect Dis (1999) 2.20
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med (1995) 2.06
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat (2001) 1.89
Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis (2006) 1.77
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology (1997) 1.74
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Am J Gastroenterol (1995) 1.53
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest (1982) 1.50
The HBV HBX gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J (1985) 1.45
Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet (1988) 1.43
Systemic but not renal production of prostacyclin is highly reduced in cyclosporin-treated heart transplant recipients. Am J Cardiol (1993) 1.39
Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med (1981) 1.34
A national survey of acute hepatitis E in France. Aliment Pharmacol Ther (2008) 1.32
Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet (1971) 1.30
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology (1999) 1.29
Clinical consequences of hepatitis C virus infection. Rev Med Virol (2003) 1.27
A simple and efficient method for platelet isolation from their plasma. Thromb Res (1980) 1.26
Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil. Am J Gastroenterol (1999) 1.26
Identification of additional antigenic sites on Dane particles and the tubular forms of hepatitis B surface antigen. J Gen Virol (1976) 1.25
Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang (1971) 1.23
Pseudomembranous colitis probably due to rifampicin. Lancet (1980) 1.22
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21
Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol (1997) 1.20
Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem (1989) 1.18
Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases. Antimicrob Agents Chemother (1984) 1.18
Comparison of HIV detection by virus isolation in lymphocyte cultures and molecular amplification of HIV DNA and RNA by PCR in offspring of seropositive mothers. J Acquir Immune Defic Syndr (1991) 1.16
Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest (1997) 1.15
Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med (1994) 1.15
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother (2007) 1.14
Detection of virus-associated antigen in serum and liver of patients with non-A non-B hepatitis. Lancet (1979) 1.14
Glycoproteins of platelet membranes from Glanzmann's thrombasthenia. A comparison with normal using carbohydrate-specific or protein-specific labelling techniques and high-resolution two-dimensional gel electrophoresis. Eur J Biochem (1981) 1.13
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology (1998) 1.13
Cyclosporine induced hemolytic anemia in a liver transplant patient. Transplant Proc (1989) 1.13
Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J Viral Hepat (2003) 1.12
Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut (2003) 1.11
Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology (1999) 1.09
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke (1998) 1.08
Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Med Interne (Paris) (1992) 1.07
Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res (1984) 1.07
Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis (1975) 1.06
Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother (1990) 1.06
Letter: Detection of e antigen by immunofluorescence in cytoplasm of hepatocytes of HBsAg carriers. Lancet (1976) 1.04
One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column. J Chromatogr (1985) 1.03
Plasma viraemia as a marker of viral replication in HIV-infected individuals. AIDS (1991) 1.02
Diagnostic value of amplification of human cytomegalovirus DNA from gastrointestinal biopsies from human immunodeficiency virus-infected patients. J Clin Microbiol (1993) 1.02
Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides. Virology (1993) 1.01
Hepatitis C virus recurrence after liver transplantation. Gut (1999) 1.01
Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology (2003) 1.01
Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol (1996) 1.00
Prevalence of intestinal protozoans in French patients infected with HIV. J Acquir Immune Defic Syndr (1993) 1.00
Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. Thromb Res (1980) 0.99
Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication. Hepatology (1990) 0.99
[Australia antigen, virus hepatitis and periarteritis nodosa]. Presse Med (1970) 0.99
Monoclonal antibodies against platelet membrane glycoproteins. Characterization and effect on platelet function. Eur J Biochem (1983) 0.99
Maintenance of woodchuck hepatitis virus activity in woodchuck hepatocyte primary culture. J Gen Virol (1987) 0.98
Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol (2004) 0.97
The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis (1998) 0.97
[Letter: Cholostatic jaundice caused by carbimazole]. Nouv Presse Med (1973) 0.97
Complex formation of human thrombospondin with osteonectin. Eur J Biochem (1988) 0.96
Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes. Arthritis Rheum (1998) 0.96
Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin Infect Dis (1994) 0.95
Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing. Hepatology (1989) 0.95
Thrombocytopenia, macrothrombocytopathia, nephritis and deafness. Am J Med (1976) 0.95
Woodchuck hepatitis virus infection: serologic and histopathologic course and outcome. Eur J Clin Microbiol (1985) 0.95
[Hepatitis B antigen (HB Ag and Australia antigen). Clinical value of its detection by solid phase radioimmunoassay (R.I.A.)]. Nouv Presse Med (1973) 0.95
Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res (1994) 0.95
Testing for HCV-RNA in commercial intravenous immunoglobulins. Lancet (1993) 0.94
Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle. Virology (1998) 0.94
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat (2011) 0.94
[Significance of anti-mitochondria antibodies in liver pathology and during syphilis]. Pathol Biol (Paris) (1973) 0.93
In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology (1991) 0.93
Hepatitis B core antigen in hepatocytes of patients with chronic active hepatitis. Dig Dis Sci (1980) 0.93
Detection of human immunodeficiency virus-DNA and RNA in the skin of HIV-infected patients using the polymerase chain reaction. J Invest Dermatol (1991) 0.92
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther (2008) 0.91
Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol (1993) 0.91
Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma. J Hepatol (1997) 0.91
Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov Disord (2000) 0.91
Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology (1993) 0.90
Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis (1989) 0.90
Detection of Pneumocystis carinii DNA in blood specimens from human immunodeficiency virus-infected patients by nested PCR. J Clin Microbiol (1999) 0.90
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol (2004) 0.90